hydromorphone has been researched along with Arthritis, Degenerative in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blimke, B; Giesecke, T; Hesselbarth, S; Müller-Schwefe, GH | 1 |
| Giesecke, T; Ringe, JD; Schäfer, S; Wimmer, AM | 1 |
| Rapoport, R; Rauck, R; Thipphawong, J | 1 |
| Bansal, M; Happich, M; Klein, R; Wielage, R; Wilson, K | 1 |
| Dubois, D; Gajria, K; Kosinski, M; Sun, X; Yang, M | 1 |
| Bozkaya, D; Caro, JJ; Dubois, D; Fleischmann, J; Sabatowski, R; Ward, A | 1 |
| Hale, M; Khanna, S; Thipphawong, J; Tudor, IC | 1 |
1 review(s) available for hydromorphone and Arthritis, Degenerative
| Article | Year |
|---|---|
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Topics: Age Factors; Aged; Amitriptyline; Analgesics; Cardiovascular Diseases; Celecoxib; Chronic Disease; Clinical Trials as Topic; Cost-Benefit Analysis; Duloxetine Hydrochloride; gamma-Aminobutyric Acid; Gastrointestinal Diseases; Humans; Hydromorphone; Low Back Pain; Markov Chains; Middle Aged; Models, Economic; Naproxen; Ontario; Osteoarthritis; Outcome Assessment, Health Care; Oxycodone; Pregabalin; Pyrazoles; Quality-Adjusted Life Years; Quebec; Sulfonamides; Thiophenes | 2013 |
5 trial(s) available for hydromorphone and Arthritis, Degenerative
| Article | Year |
|---|---|
[Oral osmotic hydromorphone (OROS) in patients with chronic severe pain due to osteoarthritis under daily routine conditions].
Topics: Activities of Daily Living; Administration, Oral; Aged; Analgesics, Opioid; Chronic Pain; Disability Evaluation; Dose-Response Relationship, Drug; Female; Germany; Humans; Hydromorphone; Male; Middle Aged; Osteoarthritis; Pain Measurement; Patient Satisfaction; Retrospective Studies; Sleep | 2014 |
Use of OROS® hydromorphone in the treatment of osteoarthritis and osteoporosis: A pooled analysis of three non-interventional studies focusing on different starting doses.
Topics: Aged; Analgesics, Opioid; Dose-Response Relationship, Drug; Female; Germany; Humans; Hydromorphone; Male; Osteoarthritis; Osteoporosis; Pain; Pain Measurement; Treatment Outcome | 2012 |
Results of a double-blind, placebo-controlled, fixed-dose assessment of once-daily OROS® hydromorphone ER in patients with moderate to severe pain associated with chronic osteoarthritis.
Topics: Aged; Analgesics, Opioid; Area Under Curve; Dose-Response Relationship, Drug; Double-Blind Method; Drug Delivery Systems; Female; Humans; Hydromorphone; Male; Middle Aged; Observation; Osteoarthritis; Pain; Pain Measurement; Severity of Illness Index; Sleep Wake Disorders; Treatment Outcome | 2013 |
Mapping MOS Sleep Scale scores to SF-6D utility index.
Topics: Humans; Hydromorphone; Low Back Pain; Osteoarthritis; Quality-Adjusted Life Years; Sleep | 2007 |
Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Topics: Adult; Aged; Aged, 80 and over; Analgesics, Opioid; Chronic Disease; Delayed-Action Preparations; Female; Hip; Humans; Hydromorphone; Knee; Male; Middle Aged; Osteoarthritis; Oxycodone; Pain | 2007 |
1 other study(ies) available for hydromorphone and Arthritis, Degenerative
| Article | Year |
|---|---|
Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Topics: Analgesics, Opioid; Chronic Disease; Cohort Studies; Cost-Benefit Analysis; Delayed-Action Preparations; Germany; Humans; Hydromorphone; Osteoarthritis; Oxycodone; Pain; Sleep; Treatment Outcome | 2007 |